Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.62 |
| ▸ | ADH1A | P07327 | 5/20 | 0.62 |
| ▸ | ADH1C | P00326 | 4/20 | 0.62 |
| ▸ | ADH7 | P40394 | 3/20 | 0.62 |
| ▸ | ADH4 | P08319 | 2/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20678788 | 1.00 | ADH1B (0.62) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL13457725 | 1.00 | ADH1B (0.62) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL5639676 | 0.96 | ADH1B (0.62) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL20678957 | 0.86 | — | — | |
| SCHEMBL18924689 | 0.86 | — | — | |
| SCHEMBL18724719 | 0.79 | — | — | |
| SCHEMBL25463543 | 0.78 | ADH1B (0.34) | ADH1BADH1AADH1CADH7TSHR | |
| SCHEMBL115509 | 0.78 | — | — | |
| SCHEMBL28498446 | 0.75 | ADH1B (0.58) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL21258630 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326760-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4438117-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-10-02 | — | — | EP | disclosed |
| EP-3658557-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-06-05 | — | — | EP | disclosed |
| CN-117946115-A | TYK2 inhibitor and application thereof | 武田药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946114-A | TYK2 inhibitor and application thereof | 武田药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20220356184-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-10 | — | — | US | disclosed |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-20080319019-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| EP-1833802-A2 | 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067428-A2 | 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-11046698-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20190256519-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20190031664-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20190241577-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-10562906-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20220356184-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20190241576-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-10577373-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20250326760-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ADH1B 4590/4885ADH1A 4849/4885ADH1C 4781/4885 |
| US-20080319019-A1 | Therapeutic Agents | SDHA, GPR119, ABAT | ADH1B 370/4885ADH1A 253/4885ADH1C 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.